All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How can the hematologic toxicities with Ven+Aza be managed more effectively?
Bookmark this article
During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, and Amer M. Zeidan, Yale School of Medicine, New Haven, US. We asked, How can the hematologic toxicities with Ven+Aza be managed more effectively.
How can the hematologic toxicities with Ven+Aza be managed more effectively?
Garcia discusses data from a dose-escalation phase Ib study (NCT02942290), evaluating Ven+Aza for the treatment of treatment-naïve patients with high-risk MDS. Garcia reports the promising efficacy and safety results seen in the trial.
More about...
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox